Previous 10 | Next 10 |
2023-12-18 10:39:54 ET More on Arcutis Biotherapeutics Arcutis Biotherapeutics: Almost There, But Needs Some Fine-Tuning Arcutis Biotherapeutics, Inc. (ARQT) Q3 2023 Earnings Call Transcript Arcutis Biotherapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation...
2023-12-18 09:59:47 ET DENVER, Colo., Dec. 18, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Arcutis Biotherapeutics Inc (NASDAQ: ARQT), ZimVie Inc (NASDAQ: ZIMV), Safe & Green Development Corp (NAS...
2023-12-18 07:29:52 ET DENVER, Colo., Dec 18, 2023 ( www.247marketnews.com )- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported, after Friday’s market close, that the U.S. Food and Drug Administration (FDA) approved the new drug application (NDA) for ZORYVE (roflumilast) topi...
2023-12-18 06:09:25 ET Stock futures inched higher on Monday after the three major averages notched their seven-week winning streak Friday amid an indication that the Fed could slash interest rates at least three times next year and four cuts in 2025. Here ...
2023-12-15 19:02:32 ET More on Arcutis Biotherapeutics Arcutis Biotherapeutics: Almost There, But Needs Some Fine-Tuning Arcutis Biotherapeutics, Inc. (ARQT) Q3 2023 Earnings Call Transcript Arcutis Biotherapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation...
ZORYVE foam represents a highly effective, safe, well-tolerated, once-daily steroid-free foam for use on all affected areas of the body, including hair-bearing areas, with no limitations on duration of use ZORYVE foam provides rapid disease clearance and significant reduction in itch, one of ...
2023-12-15 08:46:33 ET Aurora Technology Acquisition ( ATAK ) +50% . Brilliant Acquisition ( BRLI ) +27% . Ikena Oncology ( IKNA ) +24% . SportsMap Tech Acquisition ( SMAP ) +14% . Pineapple Financial ( PAPL ) +1%...
2023-11-29 15:09:18 ET More on Arcutis Biotherapeutics Arcutis Biotherapeutics: Almost There, But Needs Some Fine-Tuning Arcutis Biotherapeutics, Inc. (ARQT) Q3 2023 Earnings Call Transcript Arcutis Biotherapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation...
FDA has set a PDUFA target action date of July 07, 2024 Atopic dermatitis affects approximately 16.5 million adults and 9.6 million children in the United States sNDA supported by positive efficacy and safety data from the pivotal Phase 3 INTEGUMENT-1 and INTEGUMENT-2 trials WES...
2023-11-15 13:26:19 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Some of the most exciting opportunities can be found in biotech stocks . In fact, find one with a powerful catalyst just around the corner, and you can make a good deal of money. Look a...
News, Short Squeeze, Breakout and More Instantly...
Arcutis Biotherapeutics Inc. Company Name:
ARQT Stock Symbol:
NASDAQ Market:
Arcutis Biotherapeutics Inc. Website:
Approximately 40% of the 9 million individuals in the United States with plaque psoriasis experience involvement of the scalp Once-daily ZORYVE foam significantly improved both scalp and body psoriasis in a Phase 2b and a pivotal Phase 3 trial Data also show rapid reduction in scalp itc...
WESTLAKE VILLAGE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a virtual Key Opinion Leader (KOL) event fea...
ZORYVE cream provides rapid relief, with efficacy, safety, and tolerability demonstrated up to 56 weeks of treatment ZORYVE cream rapidly and significantly reduces itch, the most bothersome symptom of atopic dermatitis (AD) Once-daily cream is for use anywhere on the body for any duration...